| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 417.3 | 381.6 | 313.5 |
| Other income | 0.5 | 2.7 | 0.5 |
| Total income | 417.9 | 384.3 | 314.0 |
| Profit before exceptional items & tax | 33.0 | 16.3 | -10.1 |
| Exceptional items | -4.5 | 0.0 | 0.0 |
| Profit before tax | 28.5 | 16.3 | -10.1 |
| Net profit | 28.5 | 16.3 | -10.1 |
| Operating margin | 6.8% | 4.2% | -3.2% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | +74.80% |
|---|---|
| Revenue, year on year | +33.10% |
| Operating profit, year on year | +406.60% |
| Operating profit, quarter on quarter | +139.00% |
NSE results filing, NSE: SOLARA. Figures extracted from the filing.
Solara Active Pharma Sciences Ltd: key numbers
- Share price
- ₹653.25
- Market cap
- ₹3,147 Cr
- Revenue (annual)
- ₹1,369 Cr
- Net profit (annual)
- ₹-7.41 Cr
- P/E (TTM)
- 85.2×Sector 46.5×
- Promoter holding
- 41.93%+0.00% QoQ
- FII holding
- 10.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Solara Active Pharma Sciences Ltd
All →Solara Active Pharma Sciences Other Announcement
Solara Active Pharma Sciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026. This disclosure details equity ownership across various investor categories.
Solara Active Pharma Sciences Earnings Call Transcript: Key Takeaways
Solara delivered its best profitability in five years despite ongoing Ibuprofen pricing and raw material challenges.
Solara Active Pharma Sciences Investor Presentation: Key Takeaways
Solara's Q2 FY27 delivered record EBITDA and PAT in five years, driven by 33% revenue growth. Base business strength offset Ibuprofen headwinds, which is now nearing breakeven.
Solara Active Pharma Sciences Employee Stock Options
Solara Active Pharma Sciences Limited allotted 8,300 equity shares under its 2018 ESOP plan. The exercise of these options realized Rs. 0.31 Crore for the company.
- Value
- ₹0.31 Cr
Solara Active Pharma Sciences Other Announcement
Solara Active Pharma received an ESG rating of 63 ('Strong' category) from Crisil ESG Ratings for the fiscal year 2026, an upgrade from the prior year.
Solara Active Pharma Sciences Capital Structure Change
Solara Active Pharma Sciences will issue a Final Reminder-cum-Forfeiture Notice to holders of partly paid-up rights equity shares regarding outstanding call money payments.